The use of mesenchymal stromal cells in treatment of lung disordersKardia, E., Zakaria, N., Halim, N. S. S. A., Widera, D. ORCID: https://orcid.org/0000-0003-1686-130X and Yahaya, B. H. (2017) The use of mesenchymal stromal cells in treatment of lung disorders. Regenerative Medicine, 12 (2). pp. 2013-2016. ISSN 1746-076X
It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing. To link to this item DOI: 10.2217/rme-2016-0112 Abstract/SummaryThe therapeutic use of mesenchymal stromal cells (MSCs) represents a promising alternative clinical strategy for treating acute and chronic lung disorders. Several pre-clinical reports demonstrated that MSCs can secrete multiple paracrine factors and that their immunomodulatory properties can support endothelial and epithelial regeneration, modulate the inflammatory cascade, and protect lungs from damage. The effects of MSC transplantation into patients suffering from lung diseases should be fully evaluated through careful assessment of safety and associated risks, which is a prerequisite for translation of pre-clinical research into clinical practise. In this article we summarise the current status of pre-clinical research and review initial MSC-based clinical trials for treating lung injuries and lung disorders.
Download Statistics DownloadsDownloads per month over past year Altmetric Deposit Details University Staff: Request a correction | Centaur Editors: Update this record |